Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01220531 · ClinicalTrials.gov registry record · NA
Thymus Transplantation Safety-Efficacy
A NA study, sponsored by Sumitomo Pharma Switzerland.
- Completed
- Registry status
- NA
- Development phase
- 29
- Enrollment target
NCT01220531 is a NA study that has completed, run by Sumitomo Pharma Switzerland. The registered enrollment target is 29 participants.
The verdict
NCT01220531, a NA study, has completed, sponsored by Sumitomo Pharma Switzerland.
- COMPLETED
- Registry status
- NA
- Development phase
- 29 participants
- Enrollment target
Study Summary
Complete DiGeorge anomaly (cDGA) is a disorder in which there is no thymus function. With no thymus function, bone marrow stem cells do not develop into educated T cells, which fight infection. Without successful treatment, patients with cDGA must remain in reverse isolation to prevent infection and subsequent death. Cultured thymus tissue with and without immunosuppression (drugs given before and after implantation) has resulted in the development of good T cell function in subjects with complete DiGeorge anomaly. This expanded access study continues cultured thymus tissue safety and efficacy research for the treatment of complete DiGeorge anomaly. Eligible participants receive cultured thymus tissue. Immune function testing is continued for one year post-implantation.
Interventions
- BIOLOGICAL Cultured Thymus Tissue
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2010-12 |
| Est. Completion | 2023-08 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01220531
The ClinicalTrials.gov registry entry for NCT01220531 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 29 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sumitomo Pharma Switzerland, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Cultured Thymus Tissue is the first listed.
NCT01220531 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01220531 about?
NCT01220531 is a clinical study titled "Thymus Transplantation Safety-Efficacy". Complete DiGeorge anomaly (cDGA) is a disorder in which there is no thymus function. With no thymus function, bone marrow stem cells do not develop into educated T cells, which fight infection. Without successful treatment, patients with cDGA must remain in reverse isolation to prevent infection and...
What is the current status of trial NCT01220531?
This trial is currently completed. It is a NA study. The enrollment target is 29 participants. The study started on 2010-12. Estimated completion is 2023-08.
What interventions are being tested in trial NCT01220531?
The interventions under investigation include: Cultured Thymus Tissue (BIOLOGICAL).
Who is sponsoring clinical trial NCT01220531?
This trial is sponsored by Sumitomo Pharma Switzerland, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.